182748-72-7

Usage

Uses

Used in Pharmaceutical Industry:
Boc-D-aspartinol 4-Benzyl Ester is used as a building block for the synthesis of peptide and protein-based drugs, particularly in the development of new pharmaceuticals for the treatment of neurological and psychiatric disorders. Its structure and properties make it a valuable component in drug discovery and design.
Used in Medicinal Chemistry:
Boc-D-aspartinol 4-Benzyl Ester is used as a versatile chemical in medicinal chemistry, contributing to the creation of new pharmaceuticals and enhancing the stability and protection of aspartic acid moieties in drug molecules.

Upstream product

• 51186-58-4 4-benzyl Boc-D-aspartate 

Downstream Products

• 1245645-62-8 (R)-3-amino-4-hydroxybutanoic acid hydrochloride 
• 207615-86-9 (R)-3-tert-Butoxycarbonylamino-4-(4-chloro-pyrrolo[2,3-d]pyrimidin-7-yl)-butyric acid benzyl ester 
• 556069-25-1 4-(3-benzoyl-5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3-tert-butoxycarbonylamino-butyric acid benzyl ester 
• 210963-56-7 benzyl (3R)-tert-butoxycarbonylamino-4-(5-cyano-2-iodophenoxy)butyric acid 
• 868837-20-1 Boc-Asp(β-OBzl)ψ[CH2N(o-NBS)]Gly(OAll) 
• 1062238-49-6 methyl (3R)-3-{[(tert-butoxy)carbonyl]amino}-4-hydroxybutanoate 
• 1059704-65-2 (R)-4-(benzyloxy)-N,N,N-trimethyl-4-oxo-2-(4-(trifluoromethyl)phenylsulfonamido)butan-1-aminium methanesulfonate 
• 1059704-48-1 (R)-4-(benzyloxy)-2-(tert-butoxycarbonylamino)-N,N,N-trimethyl-4-oxobutan-1-aminium methanesulfonate 
• 1059704-51-6 (R)-2-amino-4-(benzyloxy)-N,N,N-trimethyl-4-oxobutan-1-aminium methanesulfonate 
• 1059704-52-7 (R)-benzyl 3-(tert-butoxycarbonylamino)-4-(dimethylamino)butanoate 
• 1059704-46-9 benzyl (R)-3-((tert-butoxycarbonyl)amino)-4-((methylsulfonyl)oxy)butanoate 
• 1403953-55-8 (1S,2S)-benzyl 2-(diphenylmethylideneamino)cyclopropanecarboxylate 
• 1403953-52-5 (3R)-benzyl 3-(diphenylmethylideneamino)-4-iodobutanoate 
• 1418006-26-4 (3R)-benzyl 3-amino-4-iodobutanoate hydrochloride 

Relevant academic research and scientific papers

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

B-cell lymphoma extra large (BCL-XL) is a well-validated cancer target. However, the on-target and dose-limiting thrombocytopenia limits the use of BCL-XL inhibitors, such as ABT263, as safe and effective anticancer agents. To reduce

IMPROVED APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF

This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.

ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS

Compounds represented by Formula (I) and (II) and salts thereof are described herein. The compounds or salts of Formula (I) and (II) may be used to treat senescence-associated diseases and disorders.

Novel heteroaryl butanoic acid derivatives

The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions comprising said novel he

HETEROARYL BUTANOIC ACID DERIVATIVES AS LTA4H INHIBITORS

The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions comprising said novel he

Stereoselective synthesis of both enantiomers of trans-2- (diphenylmethylideneamino)cyclopropanecarboxylic acid using a chiral pool approach and their incorporation in dipeptides

The stereoselective synthesis of (1R,2R)- and (1S,2S)-trans-2- (diphenylmethylideneamino)cyclopropanecarboxylic acid has been accomplished in six steps starting from (2S)- and (2R)-β-benzyl N-(tert-butoxycarbonyl) aspartate, respectively. The key-step in

Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors

We previously reported on a series of cyclohexanediamine derivatives as highly potent factor Xa inhibitors. Herein, we describe the modification of the spacer moiety to discover an alternative scaffold. Ethylenediamine derivatives possessing a substituent at the C1 position in S configuration and phenylenediamine derivatives possessing a substituent at the C5 position demonstrated moderate to strong anti-fXa activity. Further SAR studies led to the identification of compound 30h which showed both good in vitro activity (fXa IC50 = 2.2 nM, PTCT2 = 3.9 μM) and in vivo antithrombotic efficacy.

Preparative synthesis of β-amino alcohols from α-amino dicarboxylic acid derivatives

A low-expensive preparative procedure has been developed for the synthesis of protected β-amino alcohols from α-amino dicarboxylic acid derivatives.

The synthesis of Fmoc-O-allyl β-serine

Two concise routes for the synthesis of the title amino acid have been developed. The first route employs Seebach's general approach [Seebach, D.; Lelais, G.; Micuch, P.; Josien-Lefebvre, D.; Rossi, F. Helv. Chim. Acta 2004, 87, 3131] with Arndt Eistert h

Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids

An inhibitor of factor Xa (fXa), the m-substituted benzamidine AXC1578 (1a), was structurally modified with the aim of increasing its potency. In particular, pyruvic acid and propionic acid substituents were incorporated into the P1 benzamidine moiety to